CobaCyte and CobOral siRNA formulations will be provided to the pharma for evaluation of gene knockdown after oral and intravenous delivery.
“The signing of this agreement serves as further validation of our previous work. We believe our innovative approach is well-suited for this pharmaceutical company and look forward to the collaborative work ahead”, said Jeffrey Davis, president and CEO, Access Pharmaceuticals.
Any successful formulation will be jointly owned by the companies and subject to a subsequent full licensing agreement. Further details are yet to be released.